Neutralizing antibodies against interferon β: fluctuation is modest and titre dependent

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Interferon beta (IFNbeta) therapy is crucial for multiple sclerosis (MS) management.
• Neutralizing antibody (NAb) titres can impact IFNbeta's therapeutic efficacy.
• NAb titre fluctuations pose challenges in long-term MS treatment.

Purpose of the Study:

• To assess NAb titre patterns in a large cohort of MS patients over 1-3 years.
• To identify the predictability of NAb status based on initial measurements.
• To understand the dynamics of NAb development and loss during IFNbeta treatment.

Main Methods:

• Analysis of NAb titres from 822 IFNbeta-treated MS patients with two NAb measurements.
• Comparison of NAb titres against a critical threshold of 150 TRU/ml, indicating loss of bioactivity.
• Evaluation of factors like IFNbeta preparation, treatment duration, and sampling interval.

Main Results:

• 15% of patients with high NAbs (>150 TRU/ml) showed titres indicating regained bioactivity.
• 6% of patients with low or undetectable NAbs shifted to titres above 150 TRU/ml, indicating potential loss of bioactivity.
• No significant differences in fluctuation patterns were observed across different IFNbeta preparations, treatment durations, or sampling intervals.

Conclusions:

• Initial NAb titres serve as a prognostic indicator for NAb status over 1-3 years.
• The choice of IFNbeta preparation does not influence the likelihood of reverting to lower NAb titres.
• Monitoring NAb titres is essential for personalized MS treatment strategies.